Title : Oral bexarotene for post-transplant cutaneous T-cell lymphoma.

Pub. Date : 2017 Sep

PMID : 28748653






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Our report is the second to describe PT-CTCL demonstrating a long-term complete response to oral bexarotene. Bexarotene TSPY like 2 Homo sapiens
2 Given its anti-carcinogenic properties and favorable toxicity profile, oral bexarotene represents an appealing treatment option for PT-CTCL refractory to skin-directed therapies. Bexarotene TSPY like 2 Homo sapiens